UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~September~~March 23, ~~2021~~2022

PARALLAX HEALTH SCIENCES, INC.

(Exact name of Company as specified in its charter)

Nevada	000-52534	46-4733512
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification Number)
	3415 S. Sepulveda Blvd, Suite 1100-6592 Los Angeles, CA 90034 (Address of principal executive offices) (888) 263-9799 (Registrant’s Telephone Number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company		þ
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.		¨

As used in this current report and unless otherwise indicated, the terms "we", "us", "our", “Company”, and “Parallax” mean Parallax Health Sciences, Inc., a Nevada corporation, and its subsidiaries, unless otherwise indicated.

ITEM 15.0102 ~~ENTRY~~DEPARTURE ~~INTO~~OF ADIRECTORS ~~MATERIAL~~OR ~~DEFINITIVE~~PRINCIPAL ~~AGREEMENT~~OFFICERS, ELECTION OF DIRECTORS; APPOINTMENT OF OFFICERS

~~The~~Election ~~disclosures~~of ~~set~~Board ~~forth~~of ~~in Item 5.02 are incorporated into this Item 1.01 by reference.~~ Directors:

~~ITEM~~Effective ~~3.02~~March ~~UNREGISTERED~~23, ~~SALES~~2022, OFat ~~EQUITY~~1:15 ~~SECURITIES~~am PST, pursuant to an Action by Written Consent of Shareholders Holding a Majority in Interest in the Company dated March 23, 2022, the following individuals were elected to serve as the Company's Board of Directors, to serve until the election of new directors by the shareholders of the Company or resignation or removal:

~~The disclosures set forth in Item 5~~·Dr.02 ~~are~~David ~~incorporated into this Item 3~~L.02 ~~by reference.~~ Stark

~~ITEM 5~~·Mr.~~02DEPARTURE~~ OFJohn ~~DIRECTORS~~L. ~~OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS~~Ogden

~~On September 23, 2021, the Company executed an Executive Agreement (the “Executive Agreement”) for the appointment of~~ ·Ms. ~~Sonia~~Calli ~~Choi as the Company’s interim Chief Executive Officer effective September 14, 2021, pursuant to a resolution of the board of directors dated September 15, 2021~~R. Bucci

The ~~Executive~~following ~~Agreement~~individuals ~~replaces~~were ~~any~~not ~~other~~re-elected agreement between Ms. Choi and the Company or any of its subsidiaries, is for an initial term of one (1) year, and provides a base compensation of $185,000 per annum. The Executive Agreement also provides for various performance bonuses, and customary employee benefits, as ~~well~~Board as performance-based stock options to purchase shares of the Company's Common Stock at an exercise price of $0.052 for a period of five (5) years from the date of grant, to be granted upon satisfactory completion of performance events. members:

~~The foregoing disclosure of the Executive Agreement set forth in this Section 5~~·Mr.02 ~~does~~Jorn ~~not purport to be complete, and is qualified in its entirety by reference to the Executive Agreement, which is filed as Exhibit 10.1 of this Current Report and incorporated by reference herein.~~Gorlach

Ms·Mr. ~~Sonia~~Nathaniel ~~Choi~~T. Bradley

~~Ms.~~Appointment ~~Choi~~of isChairman aof ~~highly~~the ~~experienced~~Board ~~executive who combines analytical business strategies with results-driven creativity to identify new opportunities to drive growth. She has played key roles in innovative startup companies,~~ and ~~has~~Election launched new initiatives for small e-commerce companies. She has also led successful business development and marketing campaigns for NASDAQ traded companies. In addition, Ms. Choi has assisted several startup companies in securing Series A & Series B funding, and has commanded D&I initiatives in the field of ~~technology.~~ Officers:

~~Ms.~~Effective ~~Choi~~March is25, a2022, ~~patented~~Dr. ~~inventor~~David ~~within~~L. ~~the~~Stark ~~technology~~was ~~sector,~~unanimously ~~and~~appointed isas ~~experienced~~Chairman inof ~~patent~~the ~~monetization~~Board and ~~patent~~elected ~~portfolio~~to ~~management. She~~serve ~~also~~as ~~has~~President aof ~~background~~the inCompany ~~the~~and ~~medical~~its ~~field~~subsidiaries. Dr. Stark formerly served as athe ~~licensed~~Company’s ~~PCA~~President ~~caregiver,~~between ~~having~~March ~~provided~~1, ~~health~~2020, ~~care~~until ~~services~~his atresignation ~~Village~~for ~~Care~~personal ~~Hospice~~reasons inon ~~New~~August ~~York~~16, as2021. The ~~well~~Company asis inpleased ~~the~~to ~~private~~welcome ~~sector~~him back.

~~Ms.~~Termination ~~Choi~~of ~~attended Boston University, majoring in Environmental Studies.~~ Officer:

~~The~~On ~~Company~~March ~~believes~~26, 2022, Ms. Sonia Choi, ~~is qualified to be~~ the Company’s interim Chief Executive Officer ~~because~~since ofSeptember ~~her~~14, ~~extensive~~2021, ~~background~~was ~~and~~terminated ~~experience~~ in ~~corporate~~her ~~leadership~~role ~~and~~as ~~development~~interim CEO.

~~Family~~Current ~~Relationships~~Directors and Officers:

~~There~~The ~~are~~following norepresents ~~family~~the ~~relationships~~Company’s ~~between~~Directors ~~Ms.~~and ~~Choi~~Officers ~~and~~after ~~any~~the effects of the ~~Company's~~changes ~~directors~~referenced ~~and officers.~~above:

~~ITEM~~Board 9of Directors Dr.~~01FINANCIAL~~ ~~STATEMENTS~~David ~~AND~~L. ~~EXHIBITS~~Stark Chairman Mr. John L. Ogden Board Member Ms. Calli R. Bucci Board Member Officers Dr. David L. Stark President Ms. Calli R. Bucci Chief Financial Officer Secretary, Treasurer

~~(d)~~Family ~~Exhibits~~Relationships

Exhibit Number	Description of Exhibit	Filing Reference
10.1	Executive Agreement dated September 14, 2021 between Parallax Health Sciences, Inc and Sonia Choi	Filed herewith.

There are no family relationships with any of the Company's Directors and Officers.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		PARALLAX HEALTH SCIENCES, INC.
Dated: September 28, 2021		/s/ Calli R. Bucci
Dated: March 28, 2022		/s/ Calli R. Bucci
		Calli R, Bucci
		Calli R. Bucci
		Chief Financial Officer

Filing Compare · PARALLAX HEALTH SCIENCES, INC.